Progenika Biopharma

What Progenika Biopharma does

Progenika Biopharma is a private, for-profit molecular biology diagnostics company founded in 2007 and headquartered in Cambridge, Massachusetts, USA. The company develops and produces molecular biology tests serving three primary clinical application areas: blood group genotyping, diagnosis of genetically complex diseases, and disease monitoring. With 51-100 employees, Progenika operates as a specialty diagnostics developer serving clinical and laboratory customers requiring advanced molecular testing capabilities, and maintains a corporate website at progenika.com.

The company's product portfolio centers on diagnostic test development and production for clinical use. Specific product names, proprietary technical platforms, regulatory clearances, pricing models, distribution channels, and named customer relationships are not disclosed in the available source material. No information is available regarding revenue, funding history, partnerships, awards, patents, or management team composition beyond a single named officer (Ramon Riera, Vice President).

Public source material directly describing Progenika Biopharma is sparse. Most aggregated web content pertaining to molecular diagnostics in this region refers to Grifols, S.A., a Spanish plasma-derived biopharmaceutical company publicly listed on NASDAQ (ticker GRFS) whose Grifols Diagnostics Solutions subsidiary focuses on diagnostic products. The available input data does not explicitly establish a corporate ownership, subsidiary, or partnership relationship between Progenika Biopharma and Grifols, and any such inference should be treated as unverified absent primary-source confirmation.

Name

Progenika Biopharma

Legal name

Grifols, S.A.

Website

https://progenika.com

Company type

Public

Founded year

1909

Operating status

Operating

Headcount range

51–100 employees

Short description

Progenika Biopharma is a private, US-based molecular biology diagnostics company that develops and produces tests for blood group genotyping, genetic disease diagnosis, and patient monitoring. Founded in 2007 and headquartered in Cambridge, the firm employs 51-100 staff.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE)

akta.pro secondary industry

Genomic & Multi-Omic Biomarkers (NGS panels, transcriptomics, proteomics, metabolomics) (HLAAAMAJ)

Keywords

• Molecular diagnostics
• Blood group genotyping
• Genetic disease testing
• Biopharma manufacturing
• Clinical molecular biology

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Core offering

Progenika Biopharma develops and produces molecular biology tests focused on blood group genotyping, diagnosis of genetic complex diseases, and monitoring applications. The company operates as a private biopharma firm based in Cambridge, United States, with 51-100 employees, supplying specialized in-vitro diagnostic products to clinical and laboratory customers.

Product overview

No product information available for Progenika Biopharma in the provided source data. The source content describes Grifols' product portfolio including plasma-derived medicines, diagnostic solutions, bio supplies, and healthcare solutions, but does not mention Progenika Biopharma products or services.

Differentiator

Problem solved

Functional benefit

Products and services

• Molecular Biology Diagnostic Tests

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights2 records

Broad incumbents

• Abbott Molecular: Abbott Molecular provides infectious disease and genetic testing on the m2000 and Alinity m platforms, overlapping with Progenika's molecular biology test focus and serving many of the same hospital and reference-lab customers.
• Bio-Rad Laboratories: Bio-Rad's Clinical Diagnostics segment supplies blood-typing reagents, immunoassays, and molecular diagnostics used in transfusion medicine; it competes in the same customer workflows and represents a broad incumbent in the molecular diagnostics space where Progenika operates.
• Roche Diagnostics: Roche Diagnostics operates one of the largest molecular diagnostics portfolios (cobas systems, genomic assays) across hospitals and reference labs; it sets the competitive benchmark for menu breadth and instrument-driven workflow integration that Progenika's assays must plug into.
• QIAGEN: QIAGEN supplies sample-prep and molecular testing technologies used across molecular diagnostics and genetic disease workflows; it is a relevant adjacent competitor for assay-component supply and complete molecular test menu expansion.
• Hologic (Gen-Probe/Diagnostic Solutions): Hologic's diagnostics franchise (Panther system, Aptima assays) operates in molecular diagnostics; while not directly in blood typing, it competes for the same molecular lab capital budgets and represents a relevant scale incumbent in the broader category.
• Thermo Fisher Scientific (Clinical Diagnostics): Thermo Fisher's clinical diagnostics business offers molecular testing platforms, reagents, and genetic disease assays; while broader than Progenika, it competes in the same molecular diagnostics buyer environments and brings substantially greater scale.
• Grifols Diagnostics Solutions: The parent division within Grifols covering Progenika; offers a broader IVD menu (immunohematology reagents, hemostasis, infectious disease serology) and shares the same customer base of blood banks and hospitals, making it the most directly aligned peer as both platform and channel.

Direct peers

• BAG Diagnostics: BAG Diagnostics specializes in molecular blood group typing assays (e.g., BAGene product line) for transfusion medicine; it overlaps directly with Progenika's core blood genotyping franchise.
• Immucor: Immucor is a global leader in transfusion and transplantation diagnostics, with deep expertise in blood group genotyping (e.g., HEA, RHCE bead chips). It is the closest direct competitor to Progenika in molecular immunohematology.
• Quotient Limited: Quotient develops the MosaiQ microarray-based transfusion diagnostics platform for blood group typing and antigen screening. It targets the same molecular immunohematology labs as Progenika and is a direct functional peer in blood group genotyping.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

• LinkedInlinkedin.com/company/progenika

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Progenika Biopharma